Table 1 Patients characteristics

Age at diagnosis

55 [32; 86]

55.5 [32; 86]

54.5 [38; 82]

0.77^a

BMI (kg/m²)

23.9 [17.3; 44.1]

24.1 [17.3; 44.1]

23.8 [19.1; 41.6]

0.96^a

Tumor size (in mm)

15 [6; 20]

15 [6; 20]

15 [10; 20]

0.59^a

 T1b

11 (10.6%)

5 (9.6%)

6 (11.5%)

1^b

 T1c

93 (89.4%)

47 (90.4%)

46 (88.5%)

Histological subtype

0.29^b

 N.S.T.

87 (83.6%)

42 (80.8%)

45 (86.5%)

 Lobular

11 (10.6%)

8 (15.4%)

3 (5.8%)

 Mixed

1 (1%)

0

1 (1.9%)

 Other

5 (4.8%)

2 (3.8%)

3 (5.8%)

Grade

0.86^b

 I

23 (22.1%)

12 (23.1%)

11 (21.2%)

 II

57 (54.8%)

27 (51.9%)

30 (57.6%)

 III

24 (23.1%)

13 (25%)

11 (21.2%)

Neoplastic emboli

33 (35.1%)

14 (31.1%)

19 (38.8%)

0.51^b

Intraductal carcinoma

75 (72.1%)

35 (67.3%)

40 (76.9%)

0.38^b

ER (%)

80 [14; 100]

80 [20; 100]

85 [14; 100]

0.64 ^a

PR (%)

60 [0; 100]

65 [0; 100]

60 [0; 100]

0.33 ^a

HER2 score

0.90^b

 0

73 (70.2%)

36 (69.2%)

37 (71.2%)

 +

22 (21.2%)

12 (23.1%)

10 (19.2%)

 ++ ISH −

9 (8.7%)

4 (7.7%)

5 (9.6%)

Ki67 (%)

19 [1; 70]

21 [1; 60]

16.5 [5; 70]

0.65 ^a

Mitotic index

8.5 [0; 100]

8 [0; 100]

9.5 [1; 60]

0.78 ^a

Surgical treatment

 Lumpectomy

95 (91.3%)

50 (96.2%)

45 (86.5%)

0.16^b

 Total mastectomy

9 (8.7%)

2 (3.8%)

7 (13.5%)

 Sentinel lymph node biopsy

53 (51%)

30 (57.7%)

23 (44.2%)

0.23^b

 Axillary lymphadenectomy

51 (49%)

22 (42.3%)

29 (55.8%)

Other treatments

 Chemotherapy

23 (22.1%)

13 (25%)

10 (19.2%)

0.63^b

 Radiotherapy

91 (87.5%)

49 (94.2%)

42 (80.8%)

0.07^b

 Endocrine therapy

96 (92.3%)

48 (92.3%)

48 (92.3%)

1^b

Evolution

 Local relapse

11 (10.6%)

0

11 (21.2%)

0.0005^b

 Controlateral relapse

3 (2.9%)

0

3 (5.8%)

0.24^b

 Axillary lymph node relapse

5 (4.8%)

0

5 (9.6%)

0.05^b

 Distant relapse

52 (50%)

0

52 (100%)

  Bone metastases

41 (39.4%)

0

41 (78.8%)

  Visceral metastases

24 (23%)

0

24 (46.2%)

Death

31 (29.8%)

0

31 (59.6%)

< 0.0001^b